Date:11/7/2012

ircumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K.  The Company disclaims any obligation to update its forward looking relationships.Misonix Contact: 

Investor Relations Contact:Richard ZarembaJoe Diaz, Lytham Partners631 694 9555

602 889 9700invest@misonix.com 

mson@lythampartners.comMISONIX, INC. And SubsidiariesConsolidated Statements of OperationsUnauditedThree Months EndedSeptember 30,2012

2011Net sales

$4,570,525

$3,217,199Cost of goods sold

1,843,899

1,453,407Gross profit

2,726,626

1,763,792Selling expenses

1,458,564

'/>"/>

SOURCE Misonix, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Misonix Announces New Distribution Agreement For Panama
2. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
3. Misonix Exhibits at Major Worldwide Spine Conference
4. Misonix Adds Industry Veteran To Management Team
5. Misonix Participates In Cleveland Spine Review
6. Misonix And Soelim Create New Distribution Alliance For South Korea
7. Misonix Inks New Distribution Agreement For Croatia And Slovenia
8. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
9. Misonix Adds 6 Spine Sales Agencies In The U.S.
10. Misonix Product Featured At Neurosurgery Congress
11. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012